East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more East Resources Acquisition Charts. Click Here for more East Resources Acquisition Charts.](/p.php?pid=staticchart&s=N%5EERES&p=8&t=15)
Top 10 Global Pharmaceutical Company Awards $1.3 Million in
Studies to eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services
Phase III Program Award Demonstrates Industry Compliance With Later Phase
Development Aspects of Recently Ratified ICH, E14 Guidance
PHILADELPHIA, July 6 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic
(ECG) collection and interpretation services, announced today that it has been
awarded more than $1.3 million in cardiac safety monitoring and services from a
top 10 global pharmaceutical organization for one of its key drug candidates in
late phase clinical trials.
The award for the Phase III program and a related Phase II trial is comprised
of a number of studies with an investigator network that spans five continents.
eRT will provide comprehensive support, including provision of 340 units of
digital 12-lead ECG equipment designed to facilitate collection of cardiac
safety data that is subsequently provided to eRT for analysis. eRT will
perform digital collection, measurement, interpretation, review, and
distribution of cardiac safety data through its EXPeRT(R) workflow enabled data
handling technology, the first solution in production that was designed
explicitly to meet emerging international regulatory guidance and technical
standards.
"This award illustrates industry response to the recently ratified ICH, E14
guidance, which specifies cardiac safety monitoring on all compounds in a
manner consistent with therapeutic area standards, regardless of Thorough QT
Study results," said Scott Grisanti, senior vice president of business
development and chief marketing officer at eRT. "In addition, the agreement
recognizes the value drug developers are placing on the ability to make program
level awards to eRT, which offers the Project Assurance delivery methodology
and global logistics and site support capabilities required to ensure success
of this critical and complex initiative."
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. The sponsor may cancel this agreement at its sole discretion. As a
result, actual results may differ materially from any financial outlooks stated
herein. Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission.
DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci of eResearchTechnology, +1-908-203-6473, or Matt
Hayden of Hayden Communications, +1-858-704-5065, for eResearchTechnology
Web site: http://www.ert.com/